Millendo Therapeutics

OverviewSuggest Edit

Millendo Therapeutics is a biopharmaceutical company. It develops a portfolio of disease-modifying therapies and treatments for specialty and orphan endocrine diseases caused by hormone dysregulation. The company merged with OvaScience.
TypePublic
Founded2012
HQAnn Arbor, MI, US
Websitemillendo.com

Latest Updates

Employees (est.) (Mar 2019)32
Revenue (FY, 2017)$295 K(-54%)
Share Price (Jul 2021)$1.1
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Millendo Therapeutics

Julia C. Owens

Julia C. Owens

President and Chief Executive Officer
Jeffery M. Brinza

Jeffery M. Brinza

Chief Administrative Officer and General Counsel
Pharis Mohideen

Pharis Mohideen

Chief Medical Officer
Thomas Hoover

Thomas Hoover

Senior Vice President, Commercial Strategy
Ryan Zeidan

Ryan Zeidan

Senior Vice President, Development
Andrew G. Spencer

Andrew G. Spencer

Senior Vice President, Preclinical Research and Development
Show more

Millendo Therapeutics Office Locations

Millendo Therapeutics has offices in Ann Arbor, Lexington, Écully and Lyon
Ann Arbor, MI, US (HQ)
110 Miller Ave Suite 100
Lexington, MA, US
420 Bedford St #260
Lyon, FR
8 Rue Berjon
Écully, FR
Espace Européen Batiment G, 15 Chemin du Saquin
Show all (4)

Millendo Therapeutics Financials and Metrics

Millendo Therapeutics Revenue

Millendo Therapeutics's revenue was reported to be $295 k in FY, 2017
USD

Net income (FY, 2020)

(36.4m)

Market capitalization (1-Jul-2021)

20.2m

Closing stock price (1-Jul-2021)

1.1

Cash (31-Dec-2020)

38.2m

EV

(15.3m)
Millendo Therapeutics's current market capitalization is $20.2 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

277.0k653.0k295.0k

Cost of goods sold

2.2m5.4m790.0k

Gross profit

(2.0m)(4.7m)(495.0k)

Gross profit Margin, %

(712%)(727%)(168%)
Quarterly
USDQ2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

15.0k30.0k75.0k146.0k189.0k197.0k63.0k84.0k67.0k81.0k55.0k

Cost of goods sold

35.0k116.0k940.0k1.2m1.2m1.6m269.0k274.0k112.0k54.0k44.0k

Gross profit

(20.0k)(86.0k)(865.0k)(1.0m)(1.0m)(1.4m)(206.0k)(190.0k)(45.0k)27.0k11.0k

Gross profit Margin, %

(133%)(287%)(1153%)(705%)(552%)(691%)(327%)(226%)(67%)33%20%
USDQ2, 2012

Financial Leverage

-4.4 x
Show all financial metrics

Millendo Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Millendo Therapeutics Online and Social Media Presence

Embed Graph

Millendo Therapeutics News and Updates

Thinking about buying stock in Verb Technology, Casper Sleep, Millendo Therapeutics, Lipocine, or Hepion Pharmaceuticals?

NEW YORK, July 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VERB, CSPR, TPST, LPCN, and HEPA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Millendo Therapeutics, Inc. - MLND

NEW YORK, April 2, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is...

Millendo Therapeutics Blogs

Tempest and Millendo Announce Proposed Merger Agreement

Tempest and Millendo Announce Proposed Merger Agreement Content Import Mon, 03/29/2021 - 07:00 Tempest and Millendo Announce Proposed Merger Agreement March 29, 2021 at 7:00 AM EDT This release is a backfill from a News Wire General …

Millendo Therapeutics Provides Pipeline and Business Update

Millendo Therapeutics Provides Pipeline and Business Update Content Import Tue, 01/05/2021 - 09:02 Millendo Therapeutics Provides Pipeline and Business Update January 5, 2021 at 9:00 AM EST This release is a backfill from a News Wire General …

Millendo Therapeutics Reports Third Quarter 2020 Operating and Financial Results

– Phase 1 clinical trial underway for MLE-301, a selective NK3R antagonist being studied for the treatment of vasomotor symptoms (VMS) in menopausal women – ANN ARBOR, Mich. --(BUSINESS WIRE)--Nov. 9, 2020-- Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company

Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist

– First subject dosed with MLE-301, for the treatment of vasomotor symptoms (VMS) in menopausal women – – Phase 1 study will evaluate safety, pharmacokinetics and preliminary efficacy – ANN ARBOR, Mich. --(BUSINESS WIRE)--Sep. 24, 2020-- Millendo Therapeutics, Inc.

Millendo Therapeutics to Participate in September Investor Conferences

Millendo Therapeutics to Participate in September Investor Conferences Content Import Thu, 09/03/2020 - 08:30 Millendo Therapeutics to Participate in September Investor Conferences September 3, 2020 at 8:30 AM EDT This release is a backfill from a News Wire …

Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results

Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results Content Import Mon, 08/10/2020 - 08:30 Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results August 10, 2020 at 8:30 AM EDT This release is a backfill…
Show more

Millendo Therapeutics Frequently Asked Questions

  • When was Millendo Therapeutics founded?

    Millendo Therapeutics was founded in 2012.

  • Who are Millendo Therapeutics key executives?

    Millendo Therapeutics's key executives are Julia C. Owens, Jeffery M. Brinza and Pharis Mohideen.

  • How many employees does Millendo Therapeutics have?

    Millendo Therapeutics has 32 employees.

  • Who are Millendo Therapeutics competitors?

    Competitors of Millendo Therapeutics include Kangstem Biotech, Carmell Therapeutics and Maravai LifeSciences.

  • Where is Millendo Therapeutics headquarters?

    Millendo Therapeutics headquarters is located at 110 Miller Ave Suite 100, Ann Arbor.

  • Where are Millendo Therapeutics offices?

    Millendo Therapeutics has offices in Ann Arbor, Lexington, Écully and Lyon.

  • How many offices does Millendo Therapeutics have?

    Millendo Therapeutics has 4 offices.